EODData

MEMBERSHIP REGISTER LOG IN

FRA, 1C0: Celyad Oncology SA

19 Aug 2026
LAST:

0.2500

CHANGE:
 0.01		OPEN:
0.2500		HIGH:
0.2500		ASK:
0.0000		VOLUME:
0
CHG(%):
4.60		PREV:
0.2390		LOW:
0.2500		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Aug 260.25000.25000.25000.25000
18 Aug 260.23900.23900.23900.23900
17 Aug 260.22800.22800.22800.22800
14 Aug 260.22900.22900.22900.22900
13 Aug 260.23000.23000.23000.23000
12 Aug 260.23000.31000.23000.31006.0K
07 Aug 260.20800.20800.20800.20800
06 Aug 260.21000.21000.21000.21000
05 Aug 260.22000.22000.22000.22000
04 Aug 260.23300.23300.23300.23300

PROFILE

Name:Celyad Oncology SA
About:Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Address:Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
Website:https://celyad.com
ISIN:BE0974260896
LEI:549300ORR0M8XF56OI64

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.246.3%
MA10:0.246.1%
MA20:0.237.3%
MA50:0.2212.1%
MA100:0.251.4%
MA200:0.2310.7%
STO9:41.18
STO14:41.18
RSI14:50.18
WPR14:-58.82
MTM14:0.00
ROC14:0.00 
ATR:0.02 
Week High:0.3124.0%
Week Low:0.239.6%
Month High:0.3124.0%
Month Low:0.2010.7%
Year High:0.4682.0%
Year Low:0.1394.6%
Volatility:25.57